Advertisement

Journal of General Internal Medicine

, Volume 29, Issue 3, pp 429–431 | Cite as

SMART Designs in Observational Studies of Opioid Therapy Duration

  • John W. Jackson
  • Joshua J. GagneEmail author
Editorial

Chronic pain affects around 100 million US adults and is associated with $635 billion in annual direct and lost productivity costs.1 With the growing acceptance of palliative treatment for pain, prescription opioid use has risen dramatically over the past decade.2 Hydrocodone plus acetaminophen is the most commonly prescribed drug in the US.3 Though effective in relieving pain, long-term opioid therapy has been linked to many safety concerns, including substance abuse, fractures, premature labor and neonatal abstinence syndrome, and deaths from accidental overdose.2

In this issue of JGIM, Scherrer and colleagues add to the litany of potential adverse events associated with long-term opioid use. Using propensity-score methods and administrative billing records, including medical encounter and prescription dispensing data from the Veterans Administration health care system (VA), the authors investigated whether duration of prescription opioid use was associated with increased risk of...

Keywords

Propensity Score Veteran Administration Health Prescription Opioid Opioid Therapy Veteran Administration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Institute of Medicine (US). Committee on Advancing Pain Research Care and Education. Relieving pain in America : a blueprint for transforming prevention, care, education, and research. Washington, DC: National Academies Press; 2011. xvii, 364 p. p.Google Scholar
  2. 2.
    Sullivan MD, Howe CQ. Opioid therapy for chronic pain in the United States: promises and perils. Pain. 2013. doi: 10.1016/j.pain.2013.09.009. PubMed PMID: 24036286.Google Scholar
  3. 3.
    IMS Institute for Healthcare Informatics. The Use of Medicines in the United States: Review of 2011. Parsippany, NJ: IMS Institute for Healthcare Informatics; 2012.Google Scholar
  4. 4.
    Scherrer JF, Svrakic DM, Freedland KE, Chrusciel T, Balasubramanian S, Bucholz KK, et al. Prescription opioid analgesics increase the risk of depression. J Gen Intern Med. 2013. doi: 10.1007/s11606-013-2648-1. PubMed PMID: 24165926.PubMedGoogle Scholar
  5. 5.
    Rosenbaum P. Delimnas and Craftsmanship. Design of Observational Studies. New York, NY: Springer; 2010:3–13.Google Scholar
  6. 6.
    Almirall D, Compton SN, Rynn MA, Walkup JT, Murphy SA. SMARTer discontinuation trial designs for developing an adaptive treatment strategy. J Child Adolesc Psychopharmacol. 2012;22(5):364–74.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Rush AJ, First MB, Blacker D, American Psychiatric Association. Task Force for the Handbook of Psychiatric Measures. Handbook of psychiatric measures, vol. xxxvi. 2nd ed. Washington, DC: American Psychiatric Pub; 2008. 828 p. p.Google Scholar
  8. 8.
    Robins JM, Hernan MA. Estimation of the causal effects of time-varying exposures. In: Fitzmaurice GM, editor. Longitudinal data analysis. Chapman & Hall/CRC handbooks of modern statistical methods. Boca Raton: CRC Press; 2009:p. xiv, 618 p.Google Scholar
  9. 9.
    Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology (Cambridge, Mass). 2000;11(5):550–60.CrossRefGoogle Scholar
  10. 10.
    Joffe MM. Administrative and artificial censoring in censored regression models. Stat Med. 2001;20(15):2287–304.PubMedCrossRefGoogle Scholar
  11. 11.
    Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656–64.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Townsend L, Walkup JT, Crystal S, Olfson M. A systematic review of validated methods for identifying depression using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):163–73.PubMedCrossRefGoogle Scholar
  13. 13.
    Braden JB, Sullivan MD, Ray GT, Saunders K, Merrill J, Silverberg MJ, et al. Trends in long-term opioid therapy for noncancer pain among persons with a history of depression. Gen Hosp Psychiatry. 2009;31(6):564–70.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Hennessy S, Freeman CP, Cunningham F. US Government Claims Databases. Pharmacoepidemiology. 5th ed. Chichester, West Sussex, UK: Wiley-Blackwell; 2012:p. p.Google Scholar

Copyright information

© Society of General Internal Medicine 2014

Authors and Affiliations

  1. 1.Division of Pharmacoepidemiology and Pharmacoeconomics, Department of MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations